Protection of Novel Adenovirus Vectored Vaccine in Rats Against Wild‐Type Hepacivirus and Variant Infections
Sad23L-RHVns with prime-boost regimen protected 77.8% of rats against wild-type RHV-rn1 infection, and resolvers showed high levels and maintenance of T cell immunity against the variant. Our findings that maintenance of effective T cell immunity is required for RHV-rn1 resolution may provide insight to develop the HCV vaccine in humans.
Authors
- Chengyao Li
- Tingting Li (ORCID: https://orcid.org/0000-0001-5727-2179)
- Chaolan Liang (ORCID: https://orcid.org/0000-0002-6956-2250)
- Panli Zhang (ORCID: https://orcid.org/0000-0001-8691-8514)
- Yongshui Fu (ORCID: https://orcid.org/0000-0003-0886-2193)
- Qitao Deng
- Shikai Deng (ORCID: https://orcid.org/0000-0002-1895-2072)
- Ling Zhang (ORCID: https://orcid.org/0000-0001-6246-4378)
- Furong Zeng (ORCID: https://orcid.org/0000-0001-6621-8131)
- Meng Zhang (ORCID: https://orcid.org/0000-0002-4197-1263)
- Peng Zou (ORCID: https://orcid.org/0000-0003-1498-842X)
- Shengxue Luo (ORCID: https://orcid.org/0000-0001-7773-7092)
Institutions
- Guangzhou Blood Center (CN)
- Shenzhen Bao'an District People's Hospital (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Guangzhou Electronic Technology (China) (CN)
- Shenzhen Blood Center (CN)
- Shenzhen Third People’s Hospital (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Liver International
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1111/liv.70045
- Citations
- 2
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province